(Updated - June 3, 2022 6:58 AM EDT)

Baird analyst Jack Allen initiates coverage on Fate Therapeutics (NASDAQ: FATE) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE